Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis
We retrospectively investigated a cohort of 176 myelofibrosis patients (128 primary-PMF; 48 secondary-SMF) from five hematology centers. The presence of chronic kidney disease (CKD) was determined in addition to other clinical characteristics. CKD was present in 26.1% of MF patients and was signific...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2020-12, Vol.99 (12), p.2779-2785 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2785 |
|---|---|
| container_issue | 12 |
| container_start_page | 2779 |
| container_title | Annals of hematology |
| container_volume | 99 |
| creator | Lucijanic, Marko Galusic, Davor Krecak, Ivan Sedinic, Martina Holik, Hrvoje Perisa, Vlatka Moric Peric, Martina Zekanovic, Ivan Stoos-Veic, Tajana Kusec, Rajko |
| description | We retrospectively investigated a cohort of 176 myelofibrosis patients (128 primary-PMF; 48 secondary-SMF) from five hematology centers. The presence of chronic kidney disease (CKD) was determined in addition to other clinical characteristics. CKD was present in 26.1% of MF patients and was significantly associated with older age (
P
0.05 for all analyses). The presence of CKD was significantly associated with shorter time to arterial (HR = 3.49;
P
= 0.041) and venous thrombosis (HR = 7.08;
P
= 0.030) as well as with shorter overall survival (HR 2.08;
P
= 0.009). In multivariate analyses, CKD (HR = 1.8;
P
= 0.014) was associated with shorter survival independently of the DIPSS (HR = 2.7;
P
|
| doi_str_mv | 10.1007/s00277-020-04239-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2438992145</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2438992145</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-858e0a07bd41bc64d97e59426ee9f938c478a29cd58afe1cc3b58f4ecda85f843</originalsourceid><addsrcrecordid>eNp9kMtKxDAUhoMoOl5ewIUE3LipprlMk6WINxAE0a0hTU9mIm06Jq0yb2_G8QIuzCaQ8-U_53wIHZbktCSkOkuE0KoqCCUF4ZSpgm-gSckZLYiQfBNNiMqPIp8dtJvSCyEllZxuox1G5ZRSySbo-QGa0UKDIwTTYjcGO_g-4DTEPszaJTbOgR0STmN8828ZMaHBwzz2Xd0nn7APeGEGDyEz736Y424Jbe98HVflfbTlTJvg4OveQ09Xl48XN8Xd_fXtxfldYVklhkIKCcSQqm54Wdspb1QFQnE6BVBOMWl5JQ1VthHSOCitZbWQjoNtjBROcraHTta5i9i_jpAG3flkoW1NgH5MmnImlaIlFxk9_oO-9GPMy6-oilFC1SdF15TNe6QITi-i70xc6pLolX29tq-zff1pX6-mOPqKHusOmp8v37ozwNZAyqUwg_jb-5_YD6PVkVo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473202945</pqid></control><display><type>article</type><title>Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Lucijanic, Marko ; Galusic, Davor ; Krecak, Ivan ; Sedinic, Martina ; Holik, Hrvoje ; Perisa, Vlatka ; Moric Peric, Martina ; Zekanovic, Ivan ; Stoos-Veic, Tajana ; Kusec, Rajko</creator><creatorcontrib>Lucijanic, Marko ; Galusic, Davor ; Krecak, Ivan ; Sedinic, Martina ; Holik, Hrvoje ; Perisa, Vlatka ; Moric Peric, Martina ; Zekanovic, Ivan ; Stoos-Veic, Tajana ; Kusec, Rajko</creatorcontrib><description>We retrospectively investigated a cohort of 176 myelofibrosis patients (128 primary-PMF; 48 secondary-SMF) from five hematology centers. The presence of chronic kidney disease (CKD) was determined in addition to other clinical characteristics. CKD was present in 26.1% of MF patients and was significantly associated with older age (
P
< 0.001), higher WBC (
P
= 0.015), and its subsets (neutrophil, monocyte, and basophil counts), higher platelets (
P
= 0.001), lower albumin (
P
= 0.018), higher serum uric acid (
P
= 0.001), higher LDH (
P
= 0.022), and the presence of CV risk factors (
P
= 0.011). There was no significant association with driver mutations, degree of bone marrow fibrosis, PMF/SMF, or DIPSS risk categories (
P
> 0.05 for all analyses). The presence of CKD was significantly associated with shorter time to arterial (HR = 3.49;
P
= 0.041) and venous thrombosis (HR = 7.08;
P
= 0.030) as well as with shorter overall survival (HR 2.08;
P
= 0.009). In multivariate analyses, CKD (HR = 1.8;
P
= 0.014) was associated with shorter survival independently of the DIPSS (HR = 2.7;
P
< 0.001); its effect being more pronounced in lower (HR = 3.56;
P
= 0.036) than higher DIPSS categories (HR = 2.07;
P
= 0.023). MF patients with CKD should be candidates for active management aimed at the improvement of renal function. Prospective studies defining the optimal therapeutic approach are highly needed.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-020-04239-4</identifier><identifier>PMID: 32862283</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Cohort Studies ; Female ; Glomerular Filtration Rate - physiology ; Hematology ; Humans ; Kidney - physiology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Primary Myelofibrosis - diagnosis ; Primary Myelofibrosis - mortality ; Primary Myelofibrosis - physiopathology ; Renal Insufficiency, Chronic - diagnosis ; Renal Insufficiency, Chronic - mortality ; Renal Insufficiency, Chronic - physiopathology ; Retrospective Studies ; Survival Rate - trends ; Thrombosis ; Thrombosis - diagnosis ; Thrombosis - mortality ; Thrombosis - physiopathology</subject><ispartof>Annals of hematology, 2020-12, Vol.99 (12), p.2779-2785</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-858e0a07bd41bc64d97e59426ee9f938c478a29cd58afe1cc3b58f4ecda85f843</citedby><cites>FETCH-LOGICAL-c375t-858e0a07bd41bc64d97e59426ee9f938c478a29cd58afe1cc3b58f4ecda85f843</cites><orcidid>0000-0002-1372-2040</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-020-04239-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-020-04239-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32862283$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lucijanic, Marko</creatorcontrib><creatorcontrib>Galusic, Davor</creatorcontrib><creatorcontrib>Krecak, Ivan</creatorcontrib><creatorcontrib>Sedinic, Martina</creatorcontrib><creatorcontrib>Holik, Hrvoje</creatorcontrib><creatorcontrib>Perisa, Vlatka</creatorcontrib><creatorcontrib>Moric Peric, Martina</creatorcontrib><creatorcontrib>Zekanovic, Ivan</creatorcontrib><creatorcontrib>Stoos-Veic, Tajana</creatorcontrib><creatorcontrib>Kusec, Rajko</creatorcontrib><title>Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>We retrospectively investigated a cohort of 176 myelofibrosis patients (128 primary-PMF; 48 secondary-SMF) from five hematology centers. The presence of chronic kidney disease (CKD) was determined in addition to other clinical characteristics. CKD was present in 26.1% of MF patients and was significantly associated with older age (
P
< 0.001), higher WBC (
P
= 0.015), and its subsets (neutrophil, monocyte, and basophil counts), higher platelets (
P
= 0.001), lower albumin (
P
= 0.018), higher serum uric acid (
P
= 0.001), higher LDH (
P
= 0.022), and the presence of CV risk factors (
P
= 0.011). There was no significant association with driver mutations, degree of bone marrow fibrosis, PMF/SMF, or DIPSS risk categories (
P
> 0.05 for all analyses). The presence of CKD was significantly associated with shorter time to arterial (HR = 3.49;
P
= 0.041) and venous thrombosis (HR = 7.08;
P
= 0.030) as well as with shorter overall survival (HR 2.08;
P
= 0.009). In multivariate analyses, CKD (HR = 1.8;
P
= 0.014) was associated with shorter survival independently of the DIPSS (HR = 2.7;
P
< 0.001); its effect being more pronounced in lower (HR = 3.56;
P
= 0.036) than higher DIPSS categories (HR = 2.07;
P
= 0.023). MF patients with CKD should be candidates for active management aimed at the improvement of renal function. Prospective studies defining the optimal therapeutic approach are highly needed.</description><subject>Aged</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Glomerular Filtration Rate - physiology</subject><subject>Hematology</subject><subject>Humans</subject><subject>Kidney - physiology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Primary Myelofibrosis - diagnosis</subject><subject>Primary Myelofibrosis - mortality</subject><subject>Primary Myelofibrosis - physiopathology</subject><subject>Renal Insufficiency, Chronic - diagnosis</subject><subject>Renal Insufficiency, Chronic - mortality</subject><subject>Renal Insufficiency, Chronic - physiopathology</subject><subject>Retrospective Studies</subject><subject>Survival Rate - trends</subject><subject>Thrombosis</subject><subject>Thrombosis - diagnosis</subject><subject>Thrombosis - mortality</subject><subject>Thrombosis - physiopathology</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kMtKxDAUhoMoOl5ewIUE3LipprlMk6WINxAE0a0hTU9mIm06Jq0yb2_G8QIuzCaQ8-U_53wIHZbktCSkOkuE0KoqCCUF4ZSpgm-gSckZLYiQfBNNiMqPIp8dtJvSCyEllZxuox1G5ZRSySbo-QGa0UKDIwTTYjcGO_g-4DTEPszaJTbOgR0STmN8828ZMaHBwzz2Xd0nn7APeGEGDyEz736Y424Jbe98HVflfbTlTJvg4OveQ09Xl48XN8Xd_fXtxfldYVklhkIKCcSQqm54Wdspb1QFQnE6BVBOMWl5JQ1VthHSOCitZbWQjoNtjBROcraHTta5i9i_jpAG3flkoW1NgH5MmnImlaIlFxk9_oO-9GPMy6-oilFC1SdF15TNe6QITi-i70xc6pLolX29tq-zff1pX6-mOPqKHusOmp8v37ozwNZAyqUwg_jb-5_YD6PVkVo</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Lucijanic, Marko</creator><creator>Galusic, Davor</creator><creator>Krecak, Ivan</creator><creator>Sedinic, Martina</creator><creator>Holik, Hrvoje</creator><creator>Perisa, Vlatka</creator><creator>Moric Peric, Martina</creator><creator>Zekanovic, Ivan</creator><creator>Stoos-Veic, Tajana</creator><creator>Kusec, Rajko</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1372-2040</orcidid></search><sort><creationdate>20201201</creationdate><title>Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis</title><author>Lucijanic, Marko ; Galusic, Davor ; Krecak, Ivan ; Sedinic, Martina ; Holik, Hrvoje ; Perisa, Vlatka ; Moric Peric, Martina ; Zekanovic, Ivan ; Stoos-Veic, Tajana ; Kusec, Rajko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-858e0a07bd41bc64d97e59426ee9f938c478a29cd58afe1cc3b58f4ecda85f843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Glomerular Filtration Rate - physiology</topic><topic>Hematology</topic><topic>Humans</topic><topic>Kidney - physiology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Primary Myelofibrosis - diagnosis</topic><topic>Primary Myelofibrosis - mortality</topic><topic>Primary Myelofibrosis - physiopathology</topic><topic>Renal Insufficiency, Chronic - diagnosis</topic><topic>Renal Insufficiency, Chronic - mortality</topic><topic>Renal Insufficiency, Chronic - physiopathology</topic><topic>Retrospective Studies</topic><topic>Survival Rate - trends</topic><topic>Thrombosis</topic><topic>Thrombosis - diagnosis</topic><topic>Thrombosis - mortality</topic><topic>Thrombosis - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lucijanic, Marko</creatorcontrib><creatorcontrib>Galusic, Davor</creatorcontrib><creatorcontrib>Krecak, Ivan</creatorcontrib><creatorcontrib>Sedinic, Martina</creatorcontrib><creatorcontrib>Holik, Hrvoje</creatorcontrib><creatorcontrib>Perisa, Vlatka</creatorcontrib><creatorcontrib>Moric Peric, Martina</creatorcontrib><creatorcontrib>Zekanovic, Ivan</creatorcontrib><creatorcontrib>Stoos-Veic, Tajana</creatorcontrib><creatorcontrib>Kusec, Rajko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lucijanic, Marko</au><au>Galusic, Davor</au><au>Krecak, Ivan</au><au>Sedinic, Martina</au><au>Holik, Hrvoje</au><au>Perisa, Vlatka</au><au>Moric Peric, Martina</au><au>Zekanovic, Ivan</au><au>Stoos-Veic, Tajana</au><au>Kusec, Rajko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>99</volume><issue>12</issue><spage>2779</spage><epage>2785</epage><pages>2779-2785</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>We retrospectively investigated a cohort of 176 myelofibrosis patients (128 primary-PMF; 48 secondary-SMF) from five hematology centers. The presence of chronic kidney disease (CKD) was determined in addition to other clinical characteristics. CKD was present in 26.1% of MF patients and was significantly associated with older age (
P
< 0.001), higher WBC (
P
= 0.015), and its subsets (neutrophil, monocyte, and basophil counts), higher platelets (
P
= 0.001), lower albumin (
P
= 0.018), higher serum uric acid (
P
= 0.001), higher LDH (
P
= 0.022), and the presence of CV risk factors (
P
= 0.011). There was no significant association with driver mutations, degree of bone marrow fibrosis, PMF/SMF, or DIPSS risk categories (
P
> 0.05 for all analyses). The presence of CKD was significantly associated with shorter time to arterial (HR = 3.49;
P
= 0.041) and venous thrombosis (HR = 7.08;
P
= 0.030) as well as with shorter overall survival (HR 2.08;
P
= 0.009). In multivariate analyses, CKD (HR = 1.8;
P
= 0.014) was associated with shorter survival independently of the DIPSS (HR = 2.7;
P
< 0.001); its effect being more pronounced in lower (HR = 3.56;
P
= 0.036) than higher DIPSS categories (HR = 2.07;
P
= 0.023). MF patients with CKD should be candidates for active management aimed at the improvement of renal function. Prospective studies defining the optimal therapeutic approach are highly needed.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32862283</pmid><doi>10.1007/s00277-020-04239-4</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-1372-2040</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2020-12, Vol.99 (12), p.2779-2785 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2438992145 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Cohort Studies Female Glomerular Filtration Rate - physiology Hematology Humans Kidney - physiology Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Primary Myelofibrosis - diagnosis Primary Myelofibrosis - mortality Primary Myelofibrosis - physiopathology Renal Insufficiency, Chronic - diagnosis Renal Insufficiency, Chronic - mortality Renal Insufficiency, Chronic - physiopathology Retrospective Studies Survival Rate - trends Thrombosis Thrombosis - diagnosis Thrombosis - mortality Thrombosis - physiopathology |
| title | Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T01%3A36%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20renal%20function%20strongly%20affects%20survival%20and%20thrombosis%20in%20patients%20with%20myelofibrosis&rft.jtitle=Annals%20of%20hematology&rft.au=Lucijanic,%20Marko&rft.date=2020-12-01&rft.volume=99&rft.issue=12&rft.spage=2779&rft.epage=2785&rft.pages=2779-2785&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-020-04239-4&rft_dat=%3Cproquest_cross%3E2438992145%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473202945&rft_id=info:pmid/32862283&rfr_iscdi=true |